Second course of Accutane: relapse rates and what changes

A second course of Accutane is a full new course, with the same iPledge rules as the first one. The FDA label allows it after two months or more off treatment, when severe acne comes back or never fully left. In the largest study we could verify, about one in five patients relapsed after a first course. About one in twelve went back on isotretinoin. The strongest predictor of staying clear was the total dose over the whole course, not the size of each capsule. That last point is what makes a low-dose second course different. It can work just as well, but it usually runs longer, and every extra month is another iPledge cycle.

Our microdosing Accutane pillar answers the relapse question in one paragraph. This page is the long version, for people whose acne came back and who want to know what happens next.

Why did my acne come back after Accutane?

Acne comes back after Accutane for a meaningful minority of patients, and the timing is usually months, not days. A 2025 study in JAMA Dermatology, hosted by the NIH, followed 19,907 patients after a first isotretinoin course. Over an average of about two years, 22.5% relapsed, meaning they needed another prescription acne medicine. Only 8.2% went back on isotretinoin itself. The median time to relapse was 7.5 months after the course ended.

Smaller studies point the same way. A 2023 study of 225 patients, also on PubMed Central, found about 36% relapsed within two years. Most of those relapses came 6 to 18 months after the last capsule. A 2012 review in a dermatology journal put the usual window at six months to two or three years. None of that matches the forum line about acne coming back “immediately, not even a month” after stopping. Those posts are real, but they’re the loud minority. The FDA label says the opposite is common: acne may keep improving after a 15 to 20 week course ends.

So the honest answer has two halves. Most people who finish a course stay clear for a long time. The American Academy of Dermatology says that clearance can be permanent for some patients. A real share of people see acne return, usually inside the first year or two. If you’re in the second group, nothing went wrong with you. The studies below explain what tends to separate the two groups. It mostly comes down to how much medicine the whole course delivered.

Does the total dose decide whether acne comes back?

Yes, the total dose over the whole course is the number the studies keep naming. It predicts relapse better than the daily dose does. Dermatologists call it the cumulative dose, measured in milligrams per kilogram of body weight. The 2012 review states that lasting results depend on reaching 120 to 150 mg per kilogram. Going above 150 didn’t add any extra benefit. In one long-term study the review cites, 82% of patients under 120 mg per kilogram relapsed within ten years. Among patients who reached more than that, 30% relapsed.

The 2025 study is more measured, but it agrees on direction. Patients under 120 mg per kilogram relapsed 26.1% of the time. Patients in the 120 to 220 range relapsed 19.8% of the time. Among low-total-dose patients, 12.7% ended up back on isotretinoin, against 5.0% in the conventional group. Higher cumulative dose and longer course length were both linked to a lower relapse risk.

Stopping early is the fastest way to miss that number. The 2023 study found patients who quit their course early were about four times more likely to relapse. That’s the quiet danger of a course that’s working. The mirror looks clear at month three, the refills feel optional, and the total dose never gets reached. If you want the actual arithmetic, our comparison of low dose versus standard isotretinoin works through the cumulative dose math. This page leaves that math to that page.

Does a low daily dose mean a higher Accutane relapse rate?

Not on its own, as long as the course runs long enough to reach the same total. That’s the most useful finding in the 2025 JAMA Dermatology study. Once patients reached at least 120 mg per kilogram, a lower daily dose was not tied to more relapses or more retrials. The authors wrote that daily dosing “could be individualized to patient goals and preferences”. In plain words, the capsule size can flex, but the finish line stays where it is.

The short low-dose studies fit that picture, and they also show the trap. In a 50-patient study on 20 mg a day for three months, 90% of patients cleared most of their acne. Only 4% relapsed over the next six months. Six months is a short window, though, and three months at 20 mg is a small total dose. The 2012 review describes the other end. In one trial, 42% of patients on a very low daily dose needed retreatment, against 10% on a standard dose. Same 20-week course, very different totals, very different relapse rates.

Put the two findings together and the low-dose picture gets clear. A low daily dose for a standard-length course tends to relapse more, because the total never gets reached. A low daily dose for a longer course can match the standard course’s staying power. Which path fits you is the dermatologist’s call, based on your weight, your skin, and your labs. Nothing here is a suggestion about what number belongs on your prescription. What we can tell you is what a longer course means for your calendar, which is the rest of this page.

What does a second course of Accutane involve?

A second course of Accutane is a complete course, not a top-up, and the prescriber decides whether you need one. The FDA label says a second course may start after a period of two months or more off treatment. The label ties that to severe nodular acne that persists or comes back. It describes a normal course as 15 to 20 weeks, and the AAD says one course takes about four to five months. Nothing in the label makes a second course shorter than a first one.

The iPledge program starts over with it. Every isotretinoin prescription in the United States runs through the FDA’s iPledge program. The program doesn’t remember that you finished a course last year. For patients who can become pregnant, the FDA label requires two negative pregnancy tests before the first prescription of a course. The first is a screening test, and the second is a confirmatory test at least 30 days later. Patients on the forums call that stretch “the 30-day wait between rounds”, and it’s the part second-timers forget to budget. During the course, the label requires a pregnancy test within 7 days before each prescription. Each fill is a maximum 30-day supply. Pickup happens within the 7-day window that starts when the test sample is collected.

The AAD adds the visit rhythm: a dermatologist follow-up every 30 days, in person or by telemedicine, for the next prescription. Blood work comes back too, at every dose. The label calls for fasting lipid tests and liver tests during therapy until the response is known. The lab requisition is a separate document from your visit note. People show up to the draw site with the wrong paper constantly. Our plain-English iPledge program guide walks through the whole program, and the complete guide to Accutane covers the medication itself.

One date on the FDA’s iPledge page matters for anyone planning a course in 2026. The FDA approved a set of iPledge changes on February 9, 2026. They remove the old 19-day lockout after a missed window. They also drop the 30-day prescription window for patients who can’t become pregnant. Those changes are scheduled to take effect on November 15, 2026. Until then, the current rules apply on every fill, first course or second.

Why can a low-dose second course mean more iPledge months, not fewer?

Because the total dose is set by your weight, a smaller daily dose stretches the calendar to close the gap. Every extra month is a full iPledge cycle: a visit, a test if that applies, a prescription, and a pickup window. A gentler capsule doesn’t buy a gentler program. It buys more of the same program. Our page on low dose Accutane side effects makes the same point about dryness: milder each month, more months of it.

From running the logistics side of this every day, we can tell you where longer courses break. The program runs two clocks at once, the monthly cycle and the 7-day pickup window. People track one and get blindsided by the other. The pickup window is seven days, and most people learn that the hard way on their first fill. Missing it restarts the whole monthly cycle. Nothing warns you when a window closes, either. No email arrives from iPledge, and no text. Someone has to be watching the dates, and a long low-dose course simply has more dates to watch. Our guide to missing the iPledge prescription window covers what happens when one slips.

Second-timers have their own failure pattern, and it’s the opposite of the first-timer’s. First-timers don’t know the pickup window exists. Second-timers know the routine so well they stop reading it. The monthly attestation questions repeat word for word every month. Around month three, people click through them on autopilot, which is exactly when misclicks happen. The last month has its own trap. People decide they’re basically done, stop tracking, and the final refill dies in the window. The course ends when the last fill is in your hand, not when the mirror says so. On a low-dose course built to reach a total, that last fill is the one carrying the result.

That calendar is the whole job of our Concierge. The prescribing stays with your dermatologist and the windows stay with us. The same service covers a first course and a second one. Our page on Accutane prescription window timing lays the dates out day by day.

Can you stay on low dose Accutane forever?

The FDA label doesn’t describe an open-ended maintenance dose, so “forever” isn’t a plan the label describes. What the label describes is a 15 to 20 week course and possible continued improvement after it ends. It also allows a second course after two months or more off treatment if severe acne persists or returns. Whether any longer or repeated plan makes sense for you is a decision for your dermatologist, and we leave it there.

We understand why the question gets asked. One top Accutane forum post argues that a permanent low dose for everyone “would make the skin care industry collapse”. The fear underneath it is plain. Stopping is scary, because you can’t know you’ll stay clear until you try. The 2025 study is the best answer we have to that fear. About 78% of nearly 20,000 patients didn’t relapse within two years. Reaching the total dose was the thing that tipped the odds. The best odds don’t come from staying on the medicine indefinitely. They come from finishing the course you and your dermatologist mapped out, all the way to the last fill.

And if you do relapse, the door isn’t closed. The label allows a second course, and the studies say the second course follows the same total-dose logic as the first. The program logistics are the same ones you already survived once. Our low dose Accutane before and after page shows the month-by-month timeline of a longer course. A second run should hold fewer surprises than the first.

Is Accutane permanent, or does acne come back after the course?

For most people it holds, and for a real minority it does not. The FDA label says a single course produces complete remission in many patients, and that retreatment may be necessary for some. The largest count we can verify is a 2025 JAMA Dermatology study by Lai and Barbieri of 19,907 patients. In that study 22.5% relapsed, meaning they needed a systemic acne treatment again, and 8.2% went back on isotretinoin. The other 77.5% did not need another systemic treatment inside the study window.

The same study found the thing that tipped the odds. A higher total dose over the whole course was linked to a lower relapse rate, and the daily dose was not. Finishing the course your dermatologist mapped out, all the way to the last fill, is the part within your control. If acne does return, the FDA label allows a second course after at least 8 weeks off treatment, and the prescriber decides whether you need one. A prescription is never guaranteed. A board-certified dermatologist reviews your case within 24 hours, in all 50 states plus Guam.

Frequently asked questions

Will acne come back after Accutane?

For most people, no, or not for a long time. In the 2025 JAMA Dermatology study of 19,907 patients, 22.5% relapsed over about two years and 8.2% went back on isotretinoin. The AAD notes clearance is often prolonged and can be permanent for some patients.

How soon can you start a second course of Accutane?

The FDA label allows a second course after two months or more off treatment, when severe nodular acne persists or returns. The prescriber makes that call for each patient. For patients who can become pregnant, the label’s two pre-treatment pregnancy tests, 30 days apart, come before the first prescription.

Is a second course of Accutane more effective than the first?

We couldn’t find a verified FDA, AAD, or NIH figure for second-course success rates, so we won’t quote one. The studies we could verify say staying power tracks with total dose on a first course or a second. A second course that reaches the total has the same odds the first one would have had.

Is the Accutane relapse rate higher on a low dose?

Only when the low dose cuts the total short. In the 2025 study, once patients reached 120 mg per kilogram, a lower daily dose wasn’t linked to more relapses. A low dose for a standard-length course is where relapse rates climb.

Is there an Accutane maintenance dose?

The FDA label doesn’t describe one. It describes a 15 to 20 week course and a possible second course after two months or more off treatment. Any longer plan is a dermatologist’s decision, and every month on isotretinoin is an iPledge month regardless of dose.

Do you have to redo iPledge for a second course of Accutane?

Yes, the program rules apply to every course and every fill. That means the pregnancy tests for patients who can become pregnant, the 30-day supply, the pickup window, and the monthly visit. A second course means the same calendar again, and a low-dose second course usually means more months of it.

The bottom line

A second course of Accutane has its own label rules, yet most people never need one. About one in five patients relapse, mostly within the first year or two. The ones who reached the full total dose relapse least. A low daily dose doesn’t raise your odds of relapse on its own. It raises the number of months it takes to reach the total. Every one of those months is an iPledge cycle with its own window to hit.

If your acne came back and you’re weighing another round, the medical questions belong to a dermatologist. The calendar questions belong to us. Start your consult at thegoalisclear.com/quiz whenever you’re ready. A board-certified dermatologist reviews your skin and history. They decide whether a second course belongs in your plan, and at what dose. Our Concierge keeps every window on track from the first fill to the last.

Sources

• Lai J, Barbieri JS. Acne Relapse and Isotretinoin Retrial in Patients With Acne. JAMA Dermatology 2025, via PMC (NIH): pmc.ncbi.nlm.nih.gov/articles/PMC12004204
• Del Rosso JQ. Face to Face with Oral Isotretinoin: A Closer Look at the Spectrum of Therapeutic Outcomes and Why Some Patients Need Repeated Courses. J Clin Aesthet Dermatol 2012, via PMC (NIH): pmc.ncbi.nlm.nih.gov/articles/PMC3509883
• Ibrahim S, et al. Acne Vulgaris Relapse in Sudanese Patients Treated with Oral Isotretinoin: Rate and Predictive Factors. J Multidiscip Healthc 2023, via PMC (NIH): pmc.ncbi.nlm.nih.gov/articles/PMC10069433
• Rao PK, et al. Safety and efficacy of low-dose isotretinoin in the treatment of moderate to severe acne vulgaris. Indian J Dermatol, via PMC (NIH): pmc.ncbi.nlm.nih.gov/articles/PMC4037971
• FDA prescribing information, Absorica (isotretinoin) capsules, via DailyMed (NIH): dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ef0cff8-19c1-4441-b780-fca6c7ee1615
• FDA. iPLEDGE Risk Evaluation and Mitigation Strategy (REMS): fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/ipledge-risk-evaluation-and-mitigation-strategy-rems
• American Academy of Dermatology. Isotretinoin: overview: aad.org/public/diseases/acne/derm-treat/isotretinoin

Related from The Goal Is Clear

• Accutane for mild or hormonal acne?